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Background: There are inconsistent data on the risk factors for Clostridium difficile
infection (CDI) in the literature.
Aims: To use two C. difficile infection (CDI) case-control study groups to compare risk
factors in hospitalized patients with diarrhea across different countries.
Methods: A multi-center group of CDI cases/controls were identified by standardized
testing from seven countries from the prior EUropean, multi-center, prospective bi-annual
point prevalence study of CLostridium difficile Infection in hospitalized patients with
Diarrhea (EUCLID). A second group of CDI cases/controls was identified from a single
center in Germany [parallel study site (PSS)]. Data were extracted from the medical notes
to assess CDI risk factors. Univariate analyses and multivariate logistic regression models
were used to identify and compare risk factors between the two groups.
Results: There were 253 and 158 cases and 921 and 584 controls in the PSS and
EUCLID groups, respectively. Significant variables from univariate analyses in both groups
were age ≥65, number of antibiotics (OR 1.2 for each additional antibiotic) and prior
hospital admission (all p < 0.001). Congestive heart failure, diabetes, admission from
assisted living or Emergency Department, proton pump inhibitors, and chronic renal
disease were significant in PSS (all p < 0.05) but not EUCLID. Dementia and admitted
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with other bacterial diseases were significant in EUCLID (p< 0.05) but not PSS. Following
multivariate analyses, age ≥ 65, number of antibiotics and prior hospital admission were
consistently identified as CDI risk factors in each individual group and combined datasets.
Conclusion: Our results show that the same CDI risk factors were identified across
datasets. These were age ≥ 65 years, antibiotic use and prior hospital admission.
Importantly, the odds of developing CDI increases with each extra antibiotic prescribed.
Keywords: Clostridium difficile, risk factor, case control study, antibiotics, in-patients
INTRODUCTION
The importance of Clostridium difficile as a healthcare-associated
infection is well-established. In addition, the US Centers for
Disease Control and Prevention (CDC) has designated this
pathogen as one of the top three antibiotic resistant threats,
emphasizing its impact on both patients and the healthcare
economy (1–4).
New treatment options are being developed (5–8), but
prevention of C. difficile infection (CDI) is a key goal. Optimal
infection control practices, including antimicrobial stewardship,
can significantly reduce CDI incidence and transmission (9).
Vaccination against C. difficile and interventions to block the
deleterious effects of antibiotics on the gut microbiome are
being pursued as prevention options (6). Notably, however,
preventative approaches require appropriate identification of
patients at risk to optimize both the feasibility of clinical trials
and ultimately the cost-effectiveness of such interventions.
Some CDI risk factors have been consistently reported,
such as advancing age, hospital exposure/contact, and exposure
to antibiotics (10). Damage to the host gut microbiome
by antibiotics, and indeed certain other drugs can lead to
proliferation of C. difficile and disease (11). Although almost
all classes of antibiotics have been implicated in increasing the
risk of CDI some, such as fluoroquinolones, may be key drivers
of disease (9, 10). In the case of fluoroquinolones, which cause
relatively little damage to the gut microbiome, the proliferation
of a fluoroquinolone resistant strain resulted in outbreaks of
CDI worldwide (12). These outbreaks decreased in the UK after
the strict restriction of the use of fluoroquinolones (9). Prior
hospitalization has been demonstrated as a risk factor for CDI
even after adjusting for increasing age (13), with longer duration
of stay associated with higher risk (14). It should be noted that not
only is age a risk factor for CDI, deaths are also disproportionally
higher in the elderly population, with 84% of deaths due to CDI
in those >65 years old in 2011 (2).
In contrast some studies examining CDI risk factors have
revealed conflicting information (15–18). For example, the role
of proton pump inhibitors (PPIs) as a risk factor for CDI
is controversial, possibly due to ascertainment bias relating
to choice of control patients (19). Risk prediction models
have had variable success; models developed in single center
derivation cohorts have not proved robust in validation cohorts
(20, 21), possibly due to the selection of the derivation cohort.
Furthermore, interpretation of some CDI risk factors studies
can be complicated by the following: (1) inclusion of cases
with recurrent infection, rather than only those with primary
disease, (2) use of non-robust case definitions, and (3) use
of different diagnostic methodologies (16, 22–24). Our study
aimed to determine the risk factors for developing primary CDI
in hospitalized patients and compare the risks across distinct
patient groups.
MATERIALS AND METHODS
Case/Control Study
We used two groups of CDI cases and controls, defined
according to standardized laboratory testing, (22–24) across
multiple hospitals and countries in Europe. The first group
of cases and controls were based on a point prevalence study
of CDI [EUropean, multi-center, prospective bi-annual point
prevalence study of CLostridium difficile Infection in hospitalized
patients with Diarrhea (EUCLID)] and included 59 hospitals
in seven countries across Europe that were identified as having
higher rates of infection (Czech Republic, Germany, Hungary,
Poland, Portugal, Romania, and Slovakia) (22). The EUCLID
CDI cases and controls were collected during 2 separate days,
one in winter 2012/2013 and the other in summer 2013. The
second group of CDI cases and controls [referred to as parallel
study site (PSS)] was chosen as this center utilized the same
standardized CDI testingmethodology (23, 24) as that used in the
EUCLID study; testing was conducted between July and October
2015 at the University Hospital Cologne, Germany, a specialist
cancer center.
From these predefined patient groups, we conducted a
retrospective case-control study to determine the risk factors
for CDI in hospitalized patients. For inclusion in the study,
a case was defined as a patient with a positive result for
both glutamate dehydrogenase (GDH) and C. difficile toxins
from their diarrheal stool sample within the study period
(PSS) or on the day of sampling (EUCLID). A control was
defined as a patient who had a stool sample taken and tested
in the time period of interest at the study site which was
negative for CDI (GDH negative/toxin negative). For each
confirmed CDI case, four geographically matched controls (i.e.,
patients with diarrhea that was shown by standardized testing
not to be due to CDI) were randomly selected from each
respective hospital. Risk factor data were extracted from available
medical records via a standardized clinical report form (CRF),
and were sent to the study coordinator for upload into the
central database.
Frontiers in Public Health | www.frontiersin.org 2 July 2020 | Volume 8 | Article 293
Davies et al. Risk Factors for CDI
Analysis
The index sample was the sample that defined entry into the study
[either positive (cases) or negative (controls)]. For the analysis
population, participants were removed from control groups if
they had evidence of previous CDI within the preceding 8 weeks
or within the subsequent 8 weeks of the index sample. Cases were
classified as primary CDI where there was no positive toxin text
in the 8 weeks prior to the index sample; otherwise cases were
classified as recurrence. In addition, for the multivariate analysis
all cases that had a previous toxin positive fecal sample were
removed, so ensuring that only primary (and not recurrent) CDI
cases were included for risk factor analyses; matched controls
were not removed for this analysis.
Distribution of demographics, concomitant pathogens,
medical conditions, medical procedures, and medications were
tabulated by cases and controls. Where data were continuous
variables, means, and standard deviations were calculated; where
these data had a highly skewed distribution, medians, 25th
and 75th percentiles were also calculated. Where data were
categorical variables, the number, and percentage of participants
within each category were calculated. The percentage of missing
values was reported for each variable.
Univariate analysis was first used to assess risk factors;
continuous variables were compared between cases and controls
by t-test; where skewed, variables were also compared by Mann–
Whitney test; categorical variables were compared by chi-squared
(Fishers exact where numbers were below 5). Unadjusted odds
ratios were calculated for association of CDI with identified
variables of interest. For the multivariate analysis, unconditional
logistic regression analysis was performed using stepwise forward
selection with case/control as dependent variables, including
identified variables of interest from the univariate analysis and
a cut-off of p= 0.2. The same multivariate analysis approach was
performed for each group (PSS, EUCLID) and for the entire data
set (both groups combined).
Ethics
Ethical approval for this study was gained from the University
of Leeds (SoMREC/14/085) and in those participating countries
where it was required (Germany, Hungary, Poland, Romania, and
Slovakia). Ethical approval in Germany was sought on a regional
(state) basis, in response to different regional requirements.
RESULTS
Patient Population
There were 253 and 158 cases and 921 and 584 controls in the
PSS and EUCLID groups, respectively, after removing controls
with evidence of prior or subsequent CDI within 8 weeks (as
described in the Methods section). There were slightly more
males than females, both overall (ratio 1.26 males:1 females) and
for each group (PSS ratio 1.26, EUCLID 1.25) (Table 1). The
median age of all patients in the PSS group was significantly
older than in EUCLID patients (67 vs. 60 years, p < 0.001);
however, the median ages of cases within each group were
similar (PSS cases median age 71 vs. 72 years for EUCLID cases;
p= 0.885).
Univariate Analyses
Cases were significantly older than controls in both groups. In the
PSS and EUCLID groups, respectively, the median age of cases
was 71 and 72 years while the median age of controls was 65
and 58 years (p < 0.001 for both groups). Age ≥ 65 years was
significantly associated with cases of CDI compared with controls
(both p < 0.001, Table 2).
The reason for admission and the medical specialty ward
where the subject was located at the time index sample was taken
were examined. In the PSS group there were significantly more
cases than controls located in renal medicine/nephrology and
general surgery wards (all P < 0.05). In the EUCLID group,
there were no ward locations significantly associated with cases;
gastroenterology ward was however significantly associated with
controls (p = 0.012; Table 2). At the PSS hospital, significantly
more controls were admitted with malignant neoplasms than
cases (p = 0.017), and renal failure was the only reason
for admission that was significantly more frequent in cases
than controls (p = 0.015). In contrast, EUCLID cases were
significantly more likely to have been admitted with and have
a primary diagnosis of “bacterial disease (unspecified)” than
controls (p= 0.005 and 0.001, respectively, Table 2).
EUCLID cases were significantly more likely than controls
to be tested for CDI again after the index sample (40.7 vs.
19.3%, respectively, p < 0.001; Table 2). The length of time
between the index sample and a subsequent sample being taken
for testing was 21 days longer in cases than controls (median
37 vs. 16 days, p = 0.005; Table 3). In addition, cases were
also significantly more likely to have a positive test result for
C. difficile toxin in samples taken both before and after the
index sample (previous positive 7.6 vs. 2.1% cases and controls,
respectively, p < 0.001; post-positive 30.0 vs. 4.5% cases and
controls, respectively, p < 0.001; Table 2). Only 3.8 and 7.6% of
cases likely represent recurrence (PSS and EUCLID, respectively).
For the PSS group, cases were significantlymore likely to be tested
for CDI both before and after the index sample than controls,
possibly indicative of repeated episodes of diarrhea. Interestingly,
however, samples from PSS cases were only more likely to be
positive after an index sample. The majority of cases from both
cohorts likely represent primary infection (96.2 and 92.4% for
PSS and EUCLID, respectively).
Co-morbidities with higher prevalence in EUCLID cases than
controls were: cerebrovascular disease, urinary tract infection
(UTI), dementia, and chronic obstructive pulmonary disease
(COPD; all p < 0.05; Table 2). Co-morbidities with higher
prevalence in cases than controls in the PSS group were:
congestive heart failure, chronic kidney disease, and renal
replacement therapy, peripheral vascular disease, myocardial
infarction, and diabetes with organ damage (all p < 0.05;
Table 2). Cases in both groups were associated with higher
Charlson comorbidity scores, with 55.5 vs. 43.5% (p = 0.009) in
EUCLID patients with a score of >3, and 88.1 vs. 76.5% in the
PSS group (p < 0.001; Table 2).
Antibiotics were more likely to have been prescribed for an
infection (acute use) in cases of CDI, whereas in controls these
were significantly associated with prophylactic use (Table 2). Use
of at least one antibiotic of any class was significantly associated
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TABLE 1 | Age and gender for all participants, per group, and per cases and controls.
PSS EUCLID
Cases
(%)
Controls
(%)
Total number
of participants
Cases
(%)
Controls
(%)
Total number
of participants
Total 253 (100) 921 (100) 1174 158 (100) 584 (100) 742
Age category
<18 years 0 (0) 13 (1.4) 13 16 (10.1) 125 (21.4) 141
18–49 years 43 (17.0) 203 (22.0) 246 17 (10.8) 110 (18.8) 127
50–64 years 44 (17.4) 237 (25.7) 281 27 (17.1) 121 (20.7) 148
65–84 years 135 (53.4) 414 (45.0) 549 77 (48.7) 189 (32.4) 266
All ≥50 years 210 (83.0) 705 (76.5) 915 125 (79.1) 349 (59.8) 474
All ≥65 years 166 (65.6) 468 (50.8) 634 98 (62.0) 228 (39.0) 326
All ≥85 years 31 (12.3) 54 (5.9) 85 21 (13.3) 39 (6.7) 60
Gender
Female 105 (41.5) 415 (45.1) 520 74 (46.8) 253 (43.3) 327
Male 148 (58.5) 506 (54.9) 654 83 (52.9) 327 (56.0) 410
with cases in both groups (both p < 0.001). Broad-spectrum
antibiotics commonly associated with CDI were significantly
more likely to have been prescribed to cases than to controls
(Table 2). The median duration of antibiotic treatment (days)
was longer in cases than in controls in the PSS group only (6 vs. 4
days, p< 0.001; Table 3). Antibiotics given by the oral route were
significantly more likely to be prescribed to cases than controls in
the EUCLID group (36.5 vs. 26.8%; Table 2); no association with
route of administration was noted in the PSS group.
There was significantly more PPI use in the cases than the
controls (76.9 vs. 64.3%, p = 0.001) in the PSS group; no such
difference was seen in the EUCLID group. Duration of PPI use
(days) was longer in these PSS cases than in PSS controls (median
11 vs. 8 days, p = 0.001; Table 3). Drugs affecting the GI tract
(other than PPIs) were also more commonly prescribed in cases
than controls in both groups (PSS 64.0 vs. 55.6%, p = 0.013;
EUCLID 45.0 vs. 18.3%, p = 0.02; Table 2). Chemotherapy was
significantly more frequently seen in controls vs. cases (in both
EUCLID and PSS groups) in the preceding 12 weeks (p = 0.026
and 0.016, respectively, Table 2).
Cases were significantly more likely to have had surgery in the
preceding 12 weeks in both groups (PSS 41.1 vs. 28.1%, p< 0.001;
EUCLID 26.4 vs. 15.7%, p = 0.003). In the PSS group, elective
surgery was significantly more common in cases than controls
(78.1 vs. 67.1%, respectively, p = 0.037; Table 2). In addition,
these cases were also more likely to have had vascular surgery
than controls (22.9 vs. 10.8%, p= 0.003;Table 2), and to have had
a GI intervention (15.4 vs. 5.8%, P < 0.001; Table 2). There were
no significant differences in the frequencies of particular types of
surgery in the EUCLID group.
Multivariate Analysis
After univariate analyses, risk factors that were significantly
associated with the risk of CDI in both groups were age≥65 years
(ORs 1.84 PSS and 2.40 EUCLID), number of antibiotics (both
ORs 1.3 per additional antibiotic), cephalosporin use (ORs 2.69
and 2.21, respectively), high Charlson co-morbidity score (ORs
for score >3 2.28 and 1.63, respectively), surgery (ORs 1.78 and
1.92, respectively) and prior hospital admission (ORs 1.98 and
2.15, respectively; Table 2). In both groups antibiotics received
by cases as treatment for infection (acute use) was associated
with a significantly increased risk of CDI (ORs 2.02 and 3.75,
respectively), whereas the prophylactic use of antibiotics in
controls was associated with a decreased risk of CDI (ORs 0.70
and 0.35, respectively).
After removing all cases that had a previous toxin positive
fecal sample (potential recurrent cases removed PSS = 9,
EUCLID = 21), multivariate analysis was performed with data
for 1,885 patients (PSS = 1,165, EUCLID 721). Age ≥ 65
years, the number of antibiotics received and prior hospital
admission were the only risk factors identified in each group and
overall (both groups combined) that were significantly associated
with an increased risk of CDI (Table 4). Overall, the odds of
developing CDI increased by 1.2 for each additional antibiotic
prescribed (Table 4).
DISCUSSION
In this comparison of risk factors for CDI between a single center
and multicenter groups, the only risk factors that consistently
remained significant after multivariate analysis were age ≥ 65
years, the number of antibiotics prescribed, and prior hospital
admission. As would be expected with a disease where most cases
are related to contact with a healthcare facility, prior hospital
admission has been widely described as a risk factor for CDI
(25, 26). Increased age and concomitant antibiotics are also
frequently reported risk factors (15, 16, 18). For some authors,
the impact of antibiotics on the gut microbiome makes them
perhaps the most important risk factor (27). Indeed our study
demonstrates that the risk of CDI increased by 1.2 for each
additional antibiotic exposure (Table 4). Importantly, our results
demonstrate these particular risk factors remained significant
across different patient populations; vital information for those
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TABLE 2 | Categorical variable with a statistically significant difference between cases and controls within at least one of the participant cohorts (risk factors consistently
significant in both cohorts are shown in bold).
PSS EUCLID
Variables Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Age ≥ 65 166
(65.6)
468
(50.8)
<0.001 1.84
(1.4–2.5)
80
(63.0)
156
(37.2)
<0.001 2.40
(1.6–3.5)
Medical specialty where the
participant was located at the
time of the index sample
Infectious Diseases 1
(0.4%)
32
(3.0%)
0.005 0.110
(0.0–0.8)
20
(12.8%)
107
(18.5%)
0.095 0.646
(0.4–1.1)
Oncology 53
(21.0%)
254
(27.6%)
0.034 0.696
(0.5–1.0)
4
(2.6%)
24
(4.2%)
0.481 0.602
(0.2–1.8)
Renal Medicine/Nephrology 39
(15.4%)
85
(9.2%)
0.005 1.792
(1.2–2.7)
12
(7.7%)
29
(5.0%)
0.204 1.567
(0.8–3.2)
General Surgery 7
(2.8%)
7
(0.8%)
0.017 3.715
(1.3–10.7)
10
(6.4%)
25
(4.3%)
0.287 1.504
(0.7–3.2)
Gastroenterology 5
(2.0%)
6
(0.7%)
0.240 ns 12
(7.7%)
89
(15.4%)
0.012 0.451
(0.2–0.8)
Reason for admission
Malignant neoplasms 34
(13.5%)
185
(20.1%)
0.017 0.619
(0.4–0.9)
n/a n/a n/a n/a
Renal failure 21
(8.3%)
41
(4.5%)
0.015 1.947
(1.1–3.4)
5
(3.4%)
14
(2.6%)
0.574 1.331
(0.5–3.8)
Bacterial disease
(unspecified)
n/a n/a n/a n/a 7
(4.7%)
5
(0.9%)
0.005 5.368
(1.7–17.2)
Primary diagnosis
Heart disease 34
(13.5%)
74
(8.1%)
0.008 1.777
(1.2–2.7)
5
(3.9%)
15
(3.1%)
0.781 1.240
(0.4–3.5)
Renal failure 19
(7.5%)
38
(4.1%)
0.027 1.886
(1.1–3.3)
7
(5.5%)
16
(3.4%)
0.300 1.646
(0.7–4.1)
Complications of surgical and
medical care
17
(6.8%)
31
(34.0%)
0.017 2.068
(1.1–3.8)
n/a n/a n/a n/a
Bacterial disease
(unspecified)
14
(5.6%)
51
(5.6%)
0.977 0.999
(0.5–1.8)
10
(7.9%)
10
(2.1%)
0.001 3.878
(1.6–9.5)
Location of participant before admission
Home 134
(53.0%)
605
(65.7%)
<0.001 0.588
(0.4–0.8)
102
(72.4%)
452
(84.8%)
0.001 0.532
(0.4–0.8)
Emergency department 48
(19.0%)
106
(11.5%)
0.002 1.800
(1.2- 2.6)
10
(7.1%)
18
(3.4%)
0.057 2.125
(1.0–4.7)
Assisted living 3
(1.2%)
1
(0.1%)
0.033 11.040 1.1–106.6) 3
(2.1%)
7
(1.3%)
0.451 1.595
(0.4–6.2)
Had a previous admission 129
(51.0%)
301
(32.7%)
<0.001 1.977
(1.5–2.6)
85
(53.8%)
193
(33.0%)
<0.001 2.154
(1.5–3.1)
Diagnostic tests
Tested for CDI before the INDEX
sample
80
(31.6%)
3
(0.3%)
<0.001 220.345
(53.7–904.5)
34
(25.0%)
95
(19.1%)
0.131 1.411
(0.9–2.2)
Positive toxin test before the index
sample
9b
(3.6%)
1a
(0.1%)
0.323 32.76
(4.13-259.82)
12b
(7.6%)
2a
(2.1%)
<0.001 38.37
(8.89-165.68)
Tested for CDI after the INDEX
sample
160
(63.2%)
252
(27.4%)
<0.001 2.921
(2.1–4.0)
50
(40.7%)
88
(19.3%)
<0.001 2.856
(1.9–4.4)
Positive toxin test after the index
sample
53
(20.9%)
1a
(0.1%)
<0.001 124.3
(17.0–910.7)
15
(30.0%)
4a
(4.5%)
<0.001 8.693
(2.6–29.2)
Co-morbidities
Congestive Heart Failure 134
(53.0%)
342
(37.1%)
<0.001 1.906
(1.4–2.5)
22
(15.1%)
73
(13.9%)
0.703 1.106
(0.7–1.9)
(Continued)
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TABLE 2 | Continued
PSS EUCLID
Variables Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Chronic kidney disease 91
(36.0%)
216
(23.5%)
<0.001 1.833
(1.4–2.5)
24
(16.4%)
60
(11.4%)
0.100 1.534
(0.9–2.6)
Peripheral Vascular Disease 58
(22.9%)
148
(15.5%)
0.011 1.554
(1.1–2.2)
27
(18.5%)
69
(13.1%)
0.097 1.509
(0.9–2.5)
Chemotherapy in the 12 weeks
preceding the INDEX sample
47
(18.6%)
239
(26.0%)
0.016 0.651
(0.5–0.9)
4
(2.7%)
43
(8.2%)
0.026 0318
(0.1–0.9)
Myocardial Infarction 43
(17.0%)
95
(10.3%)
0.003 1.780
(1.2–2.6)
9
(6.2%)
23
(4.4%)
0.380 1.442
(0.7–3.2)
Renal replacement therapy
(e.g. dialysis) within 7 days of index
sample
42
(16.6%)
82
(8.9%)
<0.001 2.037
(1.4–3.0)
4
(2.7%)
15
(2.8%)
1.000 0.963
(0.3–2.9)
Diabetes with organ damage 31
(12.3%)
57
(6.2%)
0.001 2.117
(1.3–3.4)
7
(4.8%)
32
(6.1%)
0.717 0.781
(0.3–1.8)
Cerebrovascular disease 37
(14.6%)
143
(15.5%)
0.724 0.932
(0.6–1.4)
23
(15.8%)
44
(8.3%)
0.008 2.057
(1.2–3.5)
Urinary tract infection 30
(11.9%)
93
(10.1%)
0.418 1.198
(0.8–1.9)
21
(14.4%)
36
(6.8%)
0.004 2.296
(1.3–4.1)
Dementia 8
(3.2%)
31
(3.4%)
1.000 0.937
(0.4–2.1)
17
(11.6%)
26
(4.9%)
0.003 2.544
(1.3–4.8)
Chronic obstruction pulmonary
disease
26
(10.3%)
88
(9.6%)
0.731 1.084
(0.7–1.7)
17
(11.6%)
32
(6.1%)
0.021 2.042
(1.1–3.8)
Charlson Comorbidity Index
0 4
(1.6%)
65
(7.1%)
– – 31
(21.2%)
163
(30.9%)
– –
1 7
(2.8%)
41
(4.5%)
– – 19
(13.0%)
52
(9.9%)
– –
2 19
(7.5%)
110
(11.9%)
– – 8
(8.1%)
83
(15.7%)
– –
3 28
(11.1%)
105
(11.4%)
– – 13
(8.9%)
59
(11.2%)
– –
≥3 vs. <3 223
(88.1%)
705
(76.5%)
<0.001 2.277
(1.5–3.4)
81
(55.5%)
229
(43.5%)
0.009 1.627
(1.1–2.4)
≥4 vs. <4 195
(77.1%)
600
(65.1%)
<0.001 1.799
(1.3–2.5)
68
(46.6%)
170
(32.3%)
0.001 1.836
(1.3- 2.7)
Jonckheere–Terpstra
(ascending ordinal comparison
of Charlson Comorbidity index)
253
(100.0%)
921
(100.0%)
<0.001 n/a 158
(100)
584
(100)
0.0015 n/a
Antibiotics
At least one antibiotic
(any class)
240
(85.0%)
893
(74.7%)
<0.001 1.3
(1.1-1.4)
106
(67.1%)
264
(45.3%)
<0.001 1.3
(1.1-1.5)
Cephalosporins 19
(8.9%)
27
(2.9%)
0.001 2.689
(1.5–4.9)
28
(13.9%)
34
(6.8%)
0.003 2.210
(1.3–3.8)
Third Generation Cephalosporins 46
(21.6%)
120
(13.0%)
0.037 1.483
(1.0–2.2)
24
(11.9%)
47
(9.4%)
0.320 1.302
(0.8–2.2)
Other betalactams 15
(7.0%)
21
(2.3%)
0.003 2.701
(1.4–5.3)
9
(4.5%)
6
(1.2%)
0.016 3.847
(1.4–11.0)
Glycopeptides 63
(39.6%)
86
(9.3%)
<0.001 3.219
(2.2–4.6)
10
(5.0%)
35
(7.0%)
0.318 0.693
(0.3–1.4)
Fluoroquinolones 55
(25.8%)
144
(15.6%)
0.022 1.499
(1.1–2.1)
35
(17.3%)
89
(17.2%)
0.959 1.011
(0.7–1.6)
Meropenem 45
(17.8%)
99
(10.7%)
0.003 1.796
(1.2–2.6)
n/a n/a n/a n/a
(Continued)
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TABLE 2 | Continued
PSS EUCLID
Variables Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Other antibiotics 32
(13.3%)
44
(4.9%)
<0.001 2.886
(1.8–4.7)
22
(10.9%)
63
(12.6%)
0.535 0.850
(0.5–1.4)
Sulphonamides 46
(19.2%)
147
(16.5)
0.399 ns 4
(2.0%)
40
(8.0%)
0.02 0.233
(0.1–0.7)
Indication for antibiotics
Infection other than CDI 133
(31.3%)
224
(18.4%)
<0.001 2.019
(1.6–2.6)
83
(52.5)
133
(22.8)
<0.0001 3.752
(2.599–5.418)
Prophylaxis 63
(14.8%)
243
(20.0%)
0.019 0.698
(0.5–0.9)
5
(3.3%)
28
(9.0%)
0.033 0.349
(0.1–0.9)
Pneumonia 63
(14.8%)
251
(20.6%)
0.009 0.670
(0.5–0.9)
38
(25.2%)
48
(15.3%)
0.011 1.857
(1.1–3.0)
Abscess 1
(0.2%)
20
(1.6%)
0.023 0.141
(0.0–1.1)
n/a n/a n/a n/a
Fever 68
(16.0%)
239
(19.6%)
0.098 0.779
(0.6–1.0)
5
(3.3%)
25
(11.2%)
0.004 0.272
(0.1–0.7)
Neutropenia n/a n/a n/a n/a 0
(0.0%)
15
(4.8%)
0.004 1.000
Antibiotic route
IV 378
(74.0%)
1031
(74.3%)
0.873 0.981
(0.8–1.2)
97
(62.2%)
241
(73.3%)
0.013 0.600
(0.4–0.9)
Oral 127
(24.9%)
335
(24.2%)
0.752 1.039
(0.8–1.3)
57
(36.5%)
88
(26.8%)
0.028 1.577
(1.0–2.4)
Other medications
PPIs given 192
(76.9%)
592
(64.3%)
0.001 1.749
(1.3–2.4)
61
(48.8%)
202
(41.4%)
0.135 1.349
(0.9–2.0)
Indication for PPIs
Prophylaxis 194
(88.2%)
620
(96.6%)
<0.001 0.265
(0.1–4.8)
9
(52.9%)
39
(48.8%)
0.795 1.183
(0.4–3.4)
Disease of the esophagus,
duodenum and stomach
17
(7.7%)
14
(2.2%)
<0.001 3.757
(1.8–7.8)
n/a n/a n/a n/a
At least one GI drug given
(other than PPIs)
162
(64.0%)
512
(55.6%)
0.013 1.438
(1.1–1.9)
36
(30.3%)
144
(32.3%)
0.672 0.910
(0.6–1.4)
Indication for GI drugs
Constipation 108
(35.0%)
417
(43.0%)
0.012 0.713
(0.5–0.9)
1
(5.0%)
13
(18.3%)
0.290 0.235
(0.0–1.9)
Ulcer prophylaxis 7
(2.3%)
0
(0.0%)
<0.001 1.000 n/a n/a n/a n/a
Abdominal pain 16
(5.2%)
6
(0.6%)
<0.001 8.774
(3.4–22.6)
n/a n/a n/a n/a
Chemotherapy 13
(4.2%)
1
(0.1%)
<0.001 42.557
(5.5–326.7)
n/a n/a n/a n/a
Prophylaxis 23
(7.4%)
101
(10.4%)
0.125 0.692
(0.4–1.1)
9
(50.0%)
13
(18.3%)
0.020 3.650
(1.3–10.6)
Route of administration for GI drugs
IV 86
(24.3%)
249
(23.0%)
0.603 1.077
(0.8–1.4)
3
(9.4%)
26
(28.0%)
0.050 0.267
(0.1–1.0)
Oral 260
(73.5%)
800
(73.7%)
0.915 0.985(0.8–1.3) 29
(90.6%)
64
(68.8%)
0.018 4.380
(1.2–15.6)
Surgery and GI interventions
Had surgery in the preceding
12 weeks
104
(41.1%)
259
(28.1%)
<0.001 1.784
(1.3–2.4)
39
(26.4%)
82
(15.7%)
0.003 1.920
(1.2–3.0)
Elective 82
(78.1%)
173
(67.1%)
0.037 1.752
(1.0–3.0)
20
(60.6%)
35
(56.5%)
0.696 1.187
(0.5–2.8)
(Continued)
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TABLE 2 | Continued
PSS EUCLID
Variables Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Cases
[n (%)]
Controls
[n (%)]
X2
P-value
Odds ratio
(95% CI)
Acute 23
(21.9%)
85
(33.0%)
0.037 0.571
(0.3–1.0)
13
(39.4%)
27
(43.6%)
0.696 0.843
(0.4–2.0)
Surgery type
Vascular surgery 24
(22.9%)
28
(10.8%)
0.003 2.444
(1.3–4.5)
6
(14.0%)
11
(13.9%)
0.784 1.174
(0.4–3.4)
Had a GI intervention 39
(15.4%)
53
(5.8%)
<0.001 2.985
(1.9–4.6)
32
(22.5%)
79
(15.6%)
0.054 1.569
(1.0–2.5)
Nasogastric tube placement 2
(5.1%)
11
(20.8%)
0.038 0.206
(0.0–1.0)
6
(26.1%)
22
(30.1%)
0.345 0.587
(0.2–1.6)
Endoscopy 27
(69.2%)
24
(45.3%)
0.022 2.719
(1.1–6.5)
16
(69.6%)
39
(53.4%)
0.951 0.974
(0.4–2.2)
na, data not available as either not collected or wasn’t in the top ten for that cohort, so was not analyzed. Variables where there was no significance found between cases or controls
in either cohort are not displayed.
a Indicates control samples with either a previous or subsequent positive test for CDI outside the 8 week window for exclusion in the Univariate analyses.
b Indicates cases removed from multivariate analyses, to avoid inclusion of potential recurrent cases.
ns, not significant.
designing vaccine studies. Other CDI risk factors, however, were
specific to only a single group, which emphasizes the effects of
subject source on risk factor identification.
There were differences in the number of controls with
malignant neoplasm between PSS and EUCLID, as the PSS
hospital has a large cancer population. The difference in patient
mix between the single study site (PSS) and the multiple site
group (EUCLID) was also evident in the reason for admission.
In the PSS group cases were significantly more likely to have
been admitted with renal failure, whilst in the EUCLID group
cases were significantly more likely to have been admitted with
a “bacterial disease.” It could be hypothesized that patients with
acute bacterial disease are more likely to receive antibiotics and
therefore be at risk of CDI, indeed these patients had an odds
ratio of 5.37, demonstrating this increased risk of becoming a case
of CDI.
There were no co-morbidities identified as significant CDI risk
factors that were in common across the two groups, although
an increasing Charlson co-morbidity score was significantly
associated (Table 2). This is reflective of the frail nature of older
patients (who were significantly associated with CDI) and their
likely increasingly complicated clinical picture. Several of the co-
morbidities identified as risk factors, after univariate analyses,
would likely drive increased antibiotic use; such as UTI, COPD,
and diabetes (with organ damage). It is probable that diabetic
patients have a higher number of admissions to hospitals than
other patients, with leg/foot ulcers, thereby possibly driving a
higher rate of antibiotic use. Indeed, co-morbidities previously
associated with CDI have often included acute bacterial illnesses
that would necessitate the use of antibiotics (25).
Unlike the PSS cases, the cases in the EUCLID group were not
more likely to be prescribed broad spectrum agents, other than
cephalosporins and beta-lactams. The use of large quantities of
broad spectrum agents in the PSS group may again be reflective
of the patient mix in this group; namely cancer patients. In
addition, antibiotics in cases of CDI for both groups were
more likely to have been prescribed for an infection (acute
use), whereas antibiotics in controls were significantly associated
with prophylactic use. We hypothesize that this is likely due to
the shorter duration of antibiotics used for prophylaxis and/or
because some antibiotics known to increase the risk for CDI,
e.g., fluoroquinolones, are not as commonly used for prophylaxis.
This aligns with the admission data, where cases were more likely
to be admitted with acute bacterial illness.
In the PSS group, PPI use was associated with an increased
risk for CDI (OR 1.8), however there were no significant findings
associated with the use of PPIs in the EUCLID group. This may
be a reflection of the smaller totalN (sample size) in the EUCLID
group, and the different patient mix as, in total, 66.8% of patients
in the PSS group had a PPI, compared with just 42.9% of patients
in the EUCLID group. In addition, duration of PPI use in the
PSS cases was longer than the controls (median 11 vs. 8 days,
p = 0.001). It should be noted however, that although there
was no difference between PPI use in cases and controls in the
EUCLID group, the overall duration of PPI use was longer than
for the PSS group (Table 3). As described previously (19), the role
of PPI use in CDI is controversial and may reflect the potential
impact of ascertainment bias in the types of control patients in
studies of this nature.
Cases in both groups were significantly more likely to have
had surgery in the preceding 12 weeks by univariate analysis,
in agreement with previously published data (25). There were
no significant differences in the type of surgery for the EUCLID
group however, whereas the PSS cases were associated with
elective surgery, such as vascular surgery and GI intervention.
Again there were a larger overall number of patients that had
surgery in the PSS group (30.9%) than the EUCLID group
(16.3%) and these differences probably reflect the patient mix. It
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TABLE 3 | Metric variables with a statistically significant difference between cases and controls within at least one participant cohort.
PSS EUCLID
Variable Statistical test Number of days
or blood test
value (cases)
Number of days
or blood test
value (controls)
P-value Number of days
or blood test
value (cases)
Number of days
or blood test
value (controls)
P value
Days from admission to sample
tested (all participants)
T-test (mean) 15 10 <0.001 10 9 0.384
Mann–Whitney (median) 10 8 0.001 6 3 0.028
Days from admission to sample
tested (Participants admitted
from their own home)
T-test (mean) 15 11 <0.001 8 7 0.575
Mann–Whitney (median) 10 8 0.028 5 2 0.016
Days from admission to sample
tested (Participants admitted
from another Hospital)
T-test (mean) 19 10 <0.001 22 13 0.225
Mann–Whitney (median) 12 7 0.001 6 9 0.221
Days from admission to sample
tested (Participants admitted
from the Emergency department)
T-test (mean) 12 8 0.039 8 13 0.337
Mann–Whitney (median) 8 5 0.368 9 10 0.562
Days before the Index sample
when a CDI test occurred (this
could occur before the
admission of interest)
T-test (mean) 28.9 11.9 0.0003 57 30 0.002
Mann–Whitney (median) 12.5 176 0.232 37 16 0.005
Duration of antibiotics T-test (mean) 6.3 8.7 <0.001 12 13 0.900
Mann–Whitney (median) 6 4 <0.001 7 7 0.541
Duration of PPIs T-test (mean) 17 12 0.0003 104 131 0.786
Mann–Whitney (median) 11 8 0.0001 17 11 0.688
Duration of GI drugs T-test (mean) 8 5 <0.001 24 91 0.379
Mann–Whitney (median) 3 3 0.0001 4 5 0.779
Duration of steroids T-test (mean) 16 8 <0.001 12 60 0.546
Mann–Whitney (median) 7 4 <0.001 12 8 0.717
Days from surgery to Index
sample
T-test (mean) 17 12 0.002 26 19 0.090
Mann–Whitney (median) 10 8 0.125 22 15 0.131
Serum creatinine (mg/dL) T-test (mean) 2.3 1.7 0.0001 1.5 1.2 0.023
Mann–Whitney (median) 1.3 1 <0.001 1.0 0.8 0.023
White cell count (mm3 ) T-test (mean) 13.2 12.6 0.759 13.0 9.7 <0.001
Mann–Whitney (median) 11.4 9.4 <0.001 11.6 8.5 <0.001
Serum albumin (g/L) T-test (mean) 27.7 29.4 0.013 26 28.6 0.227
Mann–Whitney (median) 27 29 0.014 27 31 0.110
is important to note however, that in our study surgery was no
longer significant after multivariate analysis.
Our study does have some limitations; this was a retrospective
case/control study, and for the EUCLID group was limited to
a defined pre-set in-patient group (those that had been part
of the original EUCLID study). This therefore made matching
on age/gender very difficult, so matching for controls was
geographical only (within the same hospital). It was important
however to use this defined group as they had had their CDI
diagnosed by a standard, recommended CDI testing algorithm
(22–24). By using this defined group we removed any possible
bias that may have been added by the inclusion of patients who
were carriers of C. difficile but without true CDI (28), a potential
limitation of other risk factors studies. We also ensured that the
data was cleaned, to remove any possible recurrent cases, as the
risk factors for these may be different.
Another limitation of using retrospective patient notes is that
often the antibiotic data has been poorly recorded, and indeed
we found that to be the case. This may have led to lack of power
to associate risk of CDI with a particular class of antibiotic.
Importantly, however, we have shown that the risk of CDI is
significantly increased with each additional antibiotic added,
regardless of class, with an odds ratio of 1.2. Indeed, given the
lack of antibiotic data, this may actually be an underestimation of
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TABLE 4 | Risk factors in common across groups following multivariate analysis.
PSS
(n = 1165)
EUCLID
(n = 721)
Combined
(n = 1886)
OR (95% CI) OR (95% CI) OR (95% CI)
Age ≥ 65 1.6 (1.2–2.3) 2.5 (1.6–3.7) 1.9 (1.5–2.5)
Number of antibiotics 1.3 (1.1–1.4) 1.2 (1.1–1.4) 1.2 (1.1–1.3)
Prior hospital admission 1.9 (1.4–2.6) 1.6 (1.0–2.4) 1.7 (1.4–2.1)
Controls with evidence of prior or subsequent CDI within 8 weeks of the index sample,
and any cases with evidence of CDI positive within 8 weeks prior to the index sample were
removed from multivariate analysis.
the true impact. In addition, the pattern of antibiotic use within
an institution may have an effect on risk, however, by utilizing
the cohort of 59 hospitals, this should have reduced any bias
produced by one site. This again highlights the need to weigh
single-center studies with caution when looking at risk factor
data. The prevalence of CDI at a center may itself be a risk factor
for further cases; the design of the study did not allow for us
to determine a point prevalence rate for each center, although
those for the EUCLID cohort are well described in the original
paper (22). Once more, the multi-center cohort should limit the
possible bias caused by different prevalence rates at difference
centers. Finally, it should be noted that the collection of data from
the EUCLID cohort was 2 years earlier than the PSS cohort, which
may have influenced some of the risk factors.
This study highlights that age≥65, increased use of antibiotics
and prior hospital admission are identified as common risk
factors for developing primary CDI across different background
in-patient populations. This knowledge is vital to designing
robust and feasible phase III vaccine studies.
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